Neurophet said on the 13th that it signed a business agreement with Korea Eisai to supply dementia diagnostic services. The goal is to enable dementia diagnosis with Neurophet, which analyzes brain neural images at domestic medical institutions and health checkup centers.
Neurophet will supply Neurophet Aqua, manage its quality, and provide an operating manual for dementia testing. Korea Eisai will conduct sales and marketing activities targeting medical institutions. It will analyze the market and establish strategies.
Bin Jun-gil, co-CEO of Neurophet, said, "We will improve access to dementia testing through artificial intelligence (AI)-based brain image analysis." Ko Hong-byung, head of Korea Eisai, said, "We will manage the quality of dementia testing services and establish standardized procedures."